The techniques described herein provide for improved efficiency of iPSC production from biological cells. The approach achieves improved iPSC production efficiency by obtaining a set of cells whose cell cycles are synchronized at a specific, desired cell cycle phase, such as mitotic phase (also referred to as M phase). The efficacy with which such synchronized cells can be transformed into iPSCs is higher than for an arbitrary set of cells that comprises cells at a variety of different stages in their cycles. Accordingly, the approaches described herein allow efficient generation of iPSCs, thereby facilitating myriad technologies for personalized and regenerative medicine that rely upon the effective production of iPSCs.

The present disclosure relates to a composition for inhibiting the extension of a population doubling time of stem cells, comprising a c-Met agonist antibody as an active ingredient, and more particularly, to a medium additive for inhibiting the extension of a population doubling time of stem cells, comprising a c-Met agonist antibody as an active ingredient, a medium composition for culturing stem cells, comprising the medium additive, and a method for inhibiting the extension of a population doubling time.

Embodiments of the disclosure concern systems, methods, and/or compositions for cultivation of mammalian viruses, including at least human noroviruses and sapoviruses within the Caliciviridae family of viruses. The ex vivo culture systems include intestinal enteroids in combination with bile or a functionally active fraction or component thereof. In specific embodiments, the culture system is utilized to test inactivation compounds for therapeutic or environmental efficacy and to test contaminated comestibles and/or environmental entities for determination of the presence of infectious virus. Furthermore, antiviral compositions may be tested using systems of the disclosure, including drugs, small molecule inhibitors, and biologics such as neutralizing monoclonal antibodies.

The present invention provides methods and compositions for making proteins, preferably antibodies, more preferably anti-tumor necrosis factor alpha antibodies, and most preferably adalimumab. The present invention further provides methods and compositions for mammalian cell culture, preferably Chinese Hamster Ovary cells.

The invention relates to a method for preparing a liquid medium which is characterized by dissolving a desired component efficiently by controlling an amount of supplied oxygen, a liquid medium prepared by the preparation method, a method for culturing cells using the liquid medium prepared by the preparation method, a method for producing a physiologically active substance having desired quality using the culture method, and a physiologically active substance having desired quality produced by using the production method.

Methods of improving recombinant protein titer and cell titer in cell culture using cell culture media having reduced impurities are provided, and well as cell culture media having reduced impurities that can used for the production of a recombinant protein and cells with improved titer. The cell culture media having reduced impurities comprises a HEPES buffer, and the reduced impurities are HEPES related impurities. In certain aspects, methods and media improve protein titer, cell growth, and/or viable cell density.

The present application describes an optimized medium for growth of mammalian cells as well as polypeptide production. The cell culture medium is characterized by a Sow ratio of sodium to potassium ions, it further relates to the method of producing polypeptides using such cell culture media. Sn another aspect, the method of polypeptide production can also comprise a temperature shift and/or a pH-shift to further optimize growth and product yield.

A system and method for growing and maintaining biological material including producing a protein associated with the tissue, selecting cells associated with the tissue, expanding the cells, creating at least one tissue bio-ink including the expanded cells, printing the at least one tissue bio-ink in at least one tissue growth medium mixture, growing the tissue from the printed at least one tissue bio-ink, and maintaining viability of the tissue.

The present invention aim at providing a novel animal cell growth promoter. Specifically, a culture supernatant of an embryonic membrane derived from an avian or reptilian fertilized egg is use as an animal cell growth promoter. For example, by adding, to an animal cell culture medium, an animal cell growth promoter comprising, as an active ingredient, a culture supernatant of an embryonic membrane derived from an avian or reptilian fertilized egg, the animal cell growth can be promoted.

The present invention discloses a novel fructophilic lactic acid producing bacteria Bacillus coagulans strain FF-7 (MTCC 25235) and the process of isolation and characterization of the bacteria. The invention also discloses the biological applications/therapeutic use of fructophilic lactic acid producing bacteria in increased utilization of fructose from food stuff and in the managing disorders related to high fructose intake.